Preclinical Assessment of Dual CYP26[A1/B1] Inhibitor, DX308, As an Improved Treatment for Keratinization Disorders

Overview

Journal Skin Health Dis

Publisher Oxford University Press

Specialty Dermatology

Date 2022 Jun 6

PMID 35664983

Authors

J G S Veit

Y Poumay

D Mendes

J Kreitinger

L Walker

A Paquet

C Menigot

F Zolezzi

A S Paller

P Diaz

Affiliations

Soon will be listed here.

Abstract

Background: Retinoid-based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non-specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may address these shortcomings.

Objectives: Characterize the therapeutic potential of recently discovered, CYP26-selective RAMBA, DX308.

Materials And Methods: Preliminary in vitro assessment of potential off-target activity, metabolic and toxicologic profiling. Studies to assess safety and efficacy of topical treatment in correcting abnormal skin morphology in rhino mice. Extensive gene expression profiling by RNA sequencing and qPCR in 3D epidermis grown with keratinocytes (KCs) from keratinization disorders and healthy controls, to investigate modulation of retinoid biopathways.

Results: In vitro, DX308 does not interact with off-target nuclear receptors or CYP450s, is not genotoxic, and is stable in skin, despite vigorous hepatic metabolism. In vivo, topical DX308 induces comedolysis and epidermal thickening without apparent adverse effects. Gene expression profiling shows potent modulation of retinoid-responsive genes by DX308 in both healthy and keratinization disorder KCs. Pathway analysis suggests DX308 may inhibit inflammatory and immune responses in KCs.

Conclusions: These preliminary studies suggest that DX308 is an efficacious topical therapeutic with a favourable metabolic and safety profiles. DX308 may present an improved therapeutic alternative for the treatment of keratinization disorders and other retinoid-responsive skin ailments.

Citing Articles

A versatile, bioengineered skin reconstruction device designed for use in austere environments.

Veit J, Weidow M, Serban M Front Bioeng Biotechnol. 2023; 11:1208322.

PMID: 37362212 PMC: 10285514. DOI: 10.3389/fbioe.2023.1208322.

An In Vitro Model for Characterization of Drug Permeability across the Tympanic Membrane.

Veit J, Birru B, Singh R, Arrigali E, Serban M Pharmaceuticals (Basel). 2022; 15(9).

PMID: 36145335 PMC: 9503993. DOI: 10.3390/ph15091114.

References

Vahlquist A, Ganemo A, Virtanen M . Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol. 2008; 88(1):4-14. DOI: 10.2340/00015555-0415. View

Seiberg M, Siock P, Wisniewski S, Cauwenbergh G, Shapiro S . The effects of trypsin on apoptosis, utriculi size, and skin elasticity in the Rhino mouse. J Invest Dermatol. 1997; 109(3):370-6. DOI: 10.1111/1523-1747.ep12336244. View

Poumay Y, Dupont F, Marcoux S, Leclercq-Smekens M, Herin M, Coquette A . A simple reconstructed human epidermis: preparation of the culture model and utilization in in vitro studies. Arch Dermatol Res. 2004; 296(5):203-11. DOI: 10.1007/s00403-004-0507-y. View

Lucker G, Verfaille C, Heremans A, Vanhoutte F, Boegheim J, Steijlen P . Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol. 2005; 152(3):566-9. DOI: 10.1111/j.1365-2133.2005.06399.x. View

Dicken C, Bauer E, Hazen P, Krueger G, Marks Jr J, McGuire J . Isotretinoin treatment of Darier's disease. J Am Acad Dermatol. 1982; 6(4 Pt 2 Suppl):721-6. DOI: 10.1016/s0190-9622(82)80052-2. View

Gendimenico G, STIM T, Corbo M, Janssen B, Mezick J . A pleiotropic response is induced in F9 embryonal carcinoma cells and rhino mouse skin by All-trans-retinoic acid, a RAR agonist but not by SR11237, a RXR-selective agonist. J Invest Dermatol. 1994; 102(5):676-80. DOI: 10.1111/1523-1747.ep12374092. View

Steijlen P, Reifenschweiler D, Ramaekers F, van Muijen G, Happle R, Link M . Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic acid. A clinical and immunohistochemical study. Arch Dermatol Res. 1993; 285(4):221-6. DOI: 10.1007/BF00372013. View

Ray W, Bain G, Yao M, Gottlieb D . CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem. 1997; 272(30):18702-8. DOI: 10.1074/jbc.272.30.18702. View

Verfaille C, Vanhoutte F, Blanchet-Bardon C, van Steensel M, Steijlen P . Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol. 2007; 156(5):965-73. DOI: 10.1111/j.1365-2133.2006.07745.x. View

10.

Kligman L, Kligman A . The effect on rhino mouse skin of agents which influence keratinization and exfoliation. J Invest Dermatol. 1979; 73(5):354-8. DOI: 10.1111/1523-1747.ep12550409. View

11.

Hu J, Ge H, Newman M, Liu K . OSA: a fast and accurate alignment tool for RNA-Seq. Bioinformatics. 2012; 28(14):1933-4. DOI: 10.1093/bioinformatics/bts294. View

12.

Ashton R, Connor M, Lowe N . Histologic changes in the skin of the rhino mouse (hrrhhrrh) induced by retinoids. J Invest Dermatol. 1984; 82(6):632-5. DOI: 10.1111/1523-1747.ep12261472. View

13.

Yoshimura K, Uchida G, Okazaki M, Kitano Y, Harii K . Differential expression of heparin-binding EGF-like growth factor (HB-EGF) mRNA in normal human keratinocytes induced by a variety of natural and synthetic retinoids. Exp Dermatol. 2004; 12 Suppl 2:28-34. DOI: 10.1034/j.1600-0625.12.s2.5.x. View

14.

Lucker G, Heremans A, Boegheim P, van de Kerkhof P, Steijlen P . Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol. 1997; 136(1):71-5. View

15.

Obach R, BAXTER J, Liston T, Silber B, Jones B, Macintyre F . The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997; 283(1):46-58. View

16.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

17.

Diaz P, Huang W, Keyari C, Buttrick B, Price L, Guilloteau N . Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase. J Med Chem. 2016; 59(6):2579-95. PMC: 4836378. DOI: 10.1021/acs.jmedchem.5b01780. View

18.

Rittie L, Varani J, Kang S, Voorhees J, Fisher G . Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006; 126(4):732-9. DOI: 10.1038/sj.jid.5700202. View

19.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

20.

Bouclier M, Chatelus A, Ferracin J, Delain C, Shroot B, Hensby C . Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol. 1991; 4(2):65-73. DOI: 10.1159/000210926. View